Assessing direct medical costs of children following a new prescription of ADHD medication.

ABSTRACT:

Purpose

Attention-deficit/hyperactivity disorder (ADHD) is a prevalent childhood neurobehavioral disorder, imposing significant economic burdens on healthcare and society. This study aimed to examine healthcare resource utilisation and direct medical costs for paediatric ADHD patients in Catalonia, Spain, following their first ADHD treatment prescription.

Methods

Using real-world data from electronic healthcare records, this longitudinal register-based cohort study included all patients aged 6 to 18 years old who received a new centrally acting sympathomimetic treatment (ATC code N06BA) in the public healthcare system in Catalonia between 2016 and 2017. Healthcare resource utilisation and costs were analysed one year post-prescription, stratified by age (6-11, 12-14 and 15-1

SUBMITTER: Paut Kusturica M 

PROVIDER: S-EPMC12309166 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature